APIFINY — the only cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer.
This new technology is for use by primary care physicians, urologists, and oncologists alike.
APIFINY measures specific biological markers known to be associated with an immune system response to prostate cancer. It is well known that early detection improves long-term survival rates, therefore this technology along with current screening and detection methods, including family history, may provide additional insight for clinicians to aid in a clinical decision for determining a patient’s risk of prostate cancer.
Breakthrough Science for Assessing Cancer Risk
In the case of most cancers, the earlier the detection, the better chance for recovery. Scientific discovery has come a long way in the detection of lung, breast, and prostate cancers. However, there remains a potential for missed diagnosis. Armune BioScience was founded on the mission to improve the detection of cancer and enhance the outcome of therapies to treat cancer. Our technology is based on peer-reviewed and validated scientific research that measures specific biological markers known to be associated with an immune system response to cancer.
What is Prostate Cancer and How is it Detected?
Prostate cancer is the most common non-skin cancer in America, affecting 1-in-7 men. In this section, we provide an overview of prostate cancer and the methods currently available to test and assess risk for, diagnose, and treat the disease.